Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash & Equivalents (2021 - 2026)

bioAffinity Technologies has reported Cash & Equivalents over the past 6 years, most recently at $3.1 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 675.0% to $3.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Mar 2026, up 675.0% year-over-year, with the annual reading at $6.4 million for FY2025, 483.54% up from the prior year.
  • Cash & Equivalents was $3.1 million for Q1 2026 at bioAffinity Technologies, down from $6.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $13.5 million in Q3 2022 and troughed at $400000.0 in Q1 2025.
  • The 5-year median for Cash & Equivalents is $3.1 million (2026), against an average of $4.9 million.
  • Year-over-year, Cash & Equivalents tumbled 90.36% in 2024 and then skyrocketed 858.65% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $11.4 million in 2022, then plummeted by 75.28% to $2.8 million in 2023, then crashed by 60.83% to $1.1 million in 2024, then surged by 483.54% to $6.4 million in 2025, then tumbled by 51.94% to $3.1 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Cash & Equivalents are $3.1 million (Q1 2026), $6.4 million (Q4 2025), and $7.7 million (Q3 2025).